21/10/2014 | Press Releases
21st October 2014, Melbourne Australia
Specialty pharmaceutical company Hatchtech Pty Ltd today announced succesful completion of a Phase 2 clinical trial evaluating the ovicidal efficacy (ability to kill lice eggs) of a single 10 minute application of Xeglyze Lotion developed as a treatment for head lice infestation.
2/09/2014 | Press Releases
2nd September 2014 Melbourne, Australia
Specialty pharmaceutical company Hatchtech Pty Ltd today announced successful completion of its two pivotal Phase 3 clinical studies evaluating Xeglyze Lotion (formerly DeOvo Lotion) as a potential treatment for head lice infestation.
11/12/2013 | Press Releases
HATCHTECH RECEIVES FDA SPECIAL PROTOCOL AGREEMENT OF DEOVO PHASE III STUDIES AND STRENGTHENS PATENT PORTFOLIO
31/10/2013 | Press Releases
Hatchtech today announced the completion of a $12.6m capital raise to fund the Phase III clinical trial and NDA submission. The company also announced several changes to the composition of its Board.
13/03/2013 | Press Releases
Specialty pharmaceutical company Hatchtech Pty Ltd is pleased to announce the appointment of former Phosphagenics Vice President Mr Hugh Alsop as the company’s new Chief Executive Officer